Tarsier Pharma ^{Filed, US Offering, NYSE American: TARX}

We are a late clinical stage biopharmaceutical company, focused on the development and commercialization of novel pharmaceutical therapies to address unmet need in blinding diseases of the eye with underlying inflammatory pathologies. Our dazdotuftide platform technology is a bio-inspired immunomodulator, designed to treat blinding inflammatory ocular diseases, and is currently being developed as both eye drops (TRS01) and intravitreal injections (TRS02). For the last seven decades, the standard of care for active non-infectious anterior uveitis (“NIAU”) has remained unchanged: topical steroids. While steroids effectively resolve inflammation, they are directly associated with a critical, sight-threatening side effect known as elevated intraocular pressure (“IOP”). This steroid-induced IOP elevation may promptly progress to glaucoma. Uveitis with co-morbid glaucoma — uveitic glaucoma (“UG”) — is a condition considered the end-stage of the disease. The clinical reality is severe. Vision loss in patients with uveitic glaucoma is nearly three-fold higher than in uveitis patients without glaucoma. Clinicians are forced to treat the inflammation that causes blindness with a drug that increases the risk for blindness via glaucoma. In the United States alone, there are approximately 160,000 patients with uveitic glaucoma who are trapped in this treatment cycle.